VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
KVUE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
KVUEKenvue Inc.
$19.78$38.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

KVUE logoKenvue Inc.(KVUE)Earnings, Financials & Key Ratios

KVUE•NYSE
$19.78
26.0× P/E·Price updated Jul 7, 2026
SectorConsumer DefensiveIndustryHousehold ProductsSub-IndustryConsumer Health and Wellness Products
AboutKenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.Show more
  • Revenue$15.12B-2.1%
  • EBITDA$3.26B+32.4%
  • Net Income$1.47B+42.7%
  • EPS (Diluted)0.76+40.7%
  • Gross Margin58.13%+0.3%
  • EBITDA Margin21.56%+35.3%
  • Operating Margin17.88%+50.1%
  • Net Margin9.72%+45.8%
  • ROE14.39%+45.8%

KVUE Price & Volume

Kenvue Inc. (KVUE) stock price & volume — 10-year historical chart

Loading chart...

Stabilizing Revenue Growth Amidst Post-Separation Margin Volatility

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Healthy
Cash Flow:Improving
Primary Risk:Margin erosion from competition

Key Thesis Takeaways

  • Kenvue is currently navigating a complex transition to an independent entity, characterized by a nascent recovery in top-line growth and a stabilization of its cost structure.
  • While the company demonstrates resilient pricing power with gross margins consistently near 58%, investors should monitor the ongoing pressure on operating margins, which remain sensitive to high SG&A requirements.
  • The long-term outlook depends on the company's ability to maintain its 4.3% dividend yield while simultaneously rightsizing its balance sheet and defending market share against agile competitors.

Verdict Logic

while the company shows signs of operational stabilization with a 47.1% EPS growth in 2026Q1, the current P/E of 25.17 and the volatility in cash conversion efficiency suggest that investors should wait for more consistent margin expansion before increasing exposure.

KVUE Growth Metrics

Kenvue Inc. (KVUE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years0.89%
3 Years0.39%
TTM-0.07%

Profit CAGR

10 Years-
5 Years-
3 Years-10.7%
TTM53.6%

EPS CAGR

10 Years-
5 Years-
3 Years-11.05%
TTM54.49%

Return on Capital

10 Years8.75%
5 Years11.4%
3 Years10.96%
Last Year13.19%

KVUE Recent Earnings

Kenvue Inc. (KVUE) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.32+22.1%
$0.26
Rev
$3.9B+1.7%
$3.8B
Q1 2026
Feb 17, 2026
Metric
Actual
Est
EPS
$0.27+21.2%
$0.22
Rev
$3.8B+2.6%
$3.7B
Q4 2025
Nov 3, 2025
Metric
Actual
Est
EPS
$0.28+7.6%
$0.26
Rev
$3.8B-1.5%
$3.8B
Q3 2025
Aug 7, 2025
Metric
Actual
Est
EPS
$0.29+2.9%
$0.28
Rev
$3.8B-0.4%
$3.9B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.32vs $0.26+22.1%
$3.9Bvs $3.8B+1.7%
Q1 2026Feb 17, 2026
$0.27vs $0.22+21.2%
$3.8Bvs $3.7B+2.6%
Q4 2025Nov 3, 2025
$0.28vs $0.26+7.6%
$3.8Bvs $3.8B-1.5%
Q3 2025Aug 7, 2025
$0.29vs $0.28+2.9%
$3.8Bvs $3.9B-0.4%
Based on last 12 quarters of dataView full earnings history →

Latest KVUE News

Recent stock market news and headlines for Kenvue Inc. (KVUE)

24/7 Wall Street·18h ago
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now

Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance.

24/7 Wall Street·5 days ago
5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential

Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

Zacks Investment Research·Jun 30, 2026
5 Beauty & Cosmetics Stocks to Buy for a Stable Portfolio in 2H 2026

EL, HELE, NUS, KVUE and IPAR stand out as beauty and cosmetics stocks backed by growth strategies for 2H 2026.

247 Wallst·Jun 25, 2026
5 High-Yielding Dividend Kings Retirees and Boomers Can Buy Today and Safely Hold Forever

While many Baby Boomers have enjoyed a long bull market over the past 35 years, there comes a point when income becomes more critical than stock appreciation. The reason is simple: those who leave their careers to enjoy a well-deserved retirement lose the benefits of a regular salary and their jobs, such as 401(k) matching... 5 High-Yielding Dividend Kings Retirees and Boomers Can Buy Today and Safely Hold Forever

The Motley Fool·Jun 20, 2026
Where to Put $1,000 When the Market Is This Uncertain

Church & Dwight's volume-driven growth, Keurig Dr Pepper's expanding energy drink portfolio, and Kenvue's strong beauty segment show these companies are finding ways to grow beyond simply passing inflation on to customers. None of these stocks are likely to be overnight winners, but their strong brands, cash generation, and long-term growth opportunities make them compelling choices for investors looking to put $1,000 to work in a volatile market.

Peers Comparison

Key metrics vs top competitors for Kenvue Inc. (KVUE)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
KVUE logoKVUEKenvue Inc.Current
$19.78$37.98B26.03-2.14%9.72%14.39%4.15%
PG logoPGThe Procter & Gamble Company
$152.75$356.94B23.460.29%14.66%23.78%—
CL logoCLColgate-Palmolive Company
$95.03$76.04B36.131.4%10.04%265.78%—
CHD logoCHDChurch & Dwight Co., Inc.
$98.95$23.44B32.761.57%11.81%17.45%—
EL logoELThe Estée Lauder Companies Inc.
$84.44$30.49B-26.81-8.46%-1.67%-6.29%—
PRGO logoPRGOPerrigo Company plc
$11.19$1.55B-1.09-2.75%-43.5%-50.65%—

Compare KVUE vs Peers

Kenvue Inc. (KVUE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PG

Most directly comparable listed peer for KVUE.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare KVUE against a more recognizable public peer.

Peer Set

Compare Top 5

vs PG, CL, CHD, EL

KVUE SEC Filings & Documents

Kenvue Inc. (KVUE) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Apr 15, 2026·SEC

Material company update

Feb 17, 2026·SEC

10-K Annual Reports

1
FY 2026

Feb 20, 2026·SEC

10-Q Quarterly Reports

4
FY 2026

May 7, 2026·SEC

FY 2025

Nov 3, 2025·SEC

FY 2025

Aug 7, 2025·SEC

Get notified when KVUE posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

KVUE Frequently Asked Questions

Kenvue Inc. (KVUE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Kenvue Inc.'s revenue?

Kenvue Inc. (KVUE) reported $15.29B in revenue for fiscal year 2025. This represents a 6% increase from $14.47B in 2020.

How fast is Kenvue Inc. growing?

Kenvue Inc. (KVUE) saw revenue decline by 2.1% over the past year.

Is KVUE profitable?

Yes, Kenvue Inc. (KVUE) is profitable, generating $1.62B in net income for fiscal year 2025 (9.7% net margin).

Dividend & Returns
Does KVUE pay dividends?

Yes, Kenvue Inc. (KVUE) pays a dividend with a yield of 4.15%. This makes it attractive for income-focused investors.

What is KVUE's return on equity?

Kenvue Inc. (KVUE) has a return on equity (ROE) of 14.4%. This is reasonable for most industries.

What is Kenvue Inc.'s free cash flow?

Kenvue Inc. (KVUE) generated $1.82B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in KVUE back in 2020?

Total return calculator · dividends reinvested · 6+ years of data

See returns →